HELP (Helus Pharma) 6-Month Share Buyback Ratio: -24.23% (As of Jun. 2026 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HELP Helus Pharma Inc HELP
22 GF Score
Price $14.02
! 3 Warning Signs
View Full Analysis

What is Helus Pharma 6-Month Share Buyback Ratio?

Helus Pharma HELP +13.39% 22 6-Month Share Buyback Ratio is -24.23 as of Jun. 2026. GuruFocus rates HELP with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Helus Pharma's current 6-Month Share Buyback Ratio was -24.23%.

Helus Pharma  (NAS:HELP) 6-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Helus Pharma 6-Month Share Buyback Ratio Related Terms

HELP vs VRTX, REGN, MRNA: 6-Month Share Buyback Ratio Comparison

For the Biotechnology subindustry, Helus Pharma's 6-Month Share Buyback Ratio, along with its competitors' market caps and 6-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Helus Pharma 6-Month Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helus Pharma's 6-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Helus Pharma's 6-Month Share Buyback Ratio falls into.


HELP
22GF Score
Helus Pharma Inc HELP
6-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helus Pharma 6-Month Share Buyback Ratio Calculation

Helus Pharma's 6-Month Share Buyback Ratio for the quarter that ended in Jun. 2026 is calculated as

6-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Dec. 2025 ) - Shares Outstanding (EOP) (Jun. 2026 )) / Shares Outstanding (EOP) (Dec. 2025 )
=(49.894131 - 61.984078) / 49.894131
=-24.23%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 6-Month Share Buyback Ratio of -24.23 mean?
Helus Pharma (HELP) has a 6-Month Share Buyback Ratio of -24.23 as of Jun. 2026. The 6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. View historical data for Helus Pharma and its competitors.
Is Helus Pharma's 6-Month Share Buyback Ratio too high?
Helus Pharma's current 6-Month Share Buyback Ratio is -24.23. Overall, Helus Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Helus Pharma's 6-Month Share Buyback Ratio compare to VRTX and REGN?
Helus Pharma's 6-Month Share Buyback Ratio of -24.23 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Share Buyback Ratio for a Biotechnology company?
A good 6-Month Share Buyback Ratio depends on the Biotechnology industry context. However, 6-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Share Buyback Ratio mean?
A high 6-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. View historical data for Helus Pharma and its competitors. Helus Pharma's current 6-Month Share Buyback Ratio is -24.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helus Pharma stock overvalued right now?
Helus Pharma (HELP) has a current 6-Month Share Buyback Ratio of -24.23. The current 6-Month Share Buyback Ratio is -24.23. Helus Pharma's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Share Buyback Ratio calculated?
6-Month Share Buyback Ratio is calculated from a company's financial statements. For Helus Pharma (HELP), the current 6-Month Share Buyback Ratio is -24.23 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helus Pharma Business Description

Other Exchanges R7E:GermanyHELP:Canada
Address 100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
22GF Score

Get the complete analysis for HELP

6-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.02
Price